# Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IOVA
## Company Profile
- Ticker: IOVA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 6.74 USD
- Market cap: 1830659823.6 USD
- Last updated: 2026-08-12
## Business Overview
### Tumor-Infiltrating Lymphocyte Therapy
Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion.
### Amtagvi
Amtagvi, or lifileucel, is approved in the United States for selected patients with advanced melanoma. Iovance manufactures the therapy through a centralized cell-therapy infrastructure.
### Registrational Expansion
Lifileucel is being evaluated in non-small cell lung cancer, endometrial cancer and sarcoma. IOV-SAR-201 targets undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
### Next-Generation TILs
IOV-5001 is an IL-12-tethered TIL therapy, while IOV-4001 incorporates PD-1 inactivation. These programs aim to enhance activity in immunologically resistant tumors.
## Why The Stock Is Moving

As of Aug 12, 2026, IOVA closed up 3.85% at $6.74. No new same-company headline was identified in the current news window.

## Future Catalysts

- Australian regulatory decision for lifileucel in the first half of 2026.
- Updated IOV-LUN-202 data at a major medical meeting during 2026.
- Site activation and enrollment in IOV-SAR-201 in the third quarter of 2026.
- Initiation of Phase 1/2 enrollment for IOV-5001 in the second half of 2026.
- EMA resubmission for lifileucel during 2026 and a Swiss regulatory decision in the first half of 2027.

## Recent News
- 2026-08-06 11:01 EST — [Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-reports-record-second-quarter-2026-revenue-of-99m-busine-a6998a52) — Source: Iovance Biotherapeutics, Inc.
- 2026-07-30 12:00 EST — [Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-report-second-quarter-2026-financial-results-and-corp-17e76401) — Source: Iovance Biotherapeutics, Inc.
- 2026-07-17 21:15 EST — [Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c105f1fc) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-03 20:05 EST — [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-01 11:30 EST — [Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001) — Source: Iovance Biotherapeutics, Inc.